NUPR1 packaged in extracellular vesicles promotes murine triple-negative breast cancer in a type 1 interferon-independent manner

Abstract

Aim: This study aims to elucidate the involvement of triple-negative breast cancer (TNBC)-derived extracellular vesicles in metastasis. The loss of components in the type 1 interferon (IFN1) signaling pathway has been linked to the promotion of metastasis. However, IFN1 signaling induces immunological dormancy and promotes tumorigenesis. Our hypothesis was that TNBC cells release tumor-derived extracellular vesicles (TEVs) that promote metastasis in an IFN1-independent manner.

Methods: Two murine TNBC models and transgenic mice were used to examine the role of IFN1 in TNBC progression to metastasis. Reserpine was employed to determine the effect of TEV education on TNBC progression and overall survival. EVs from cancer cells treated with vehicle and reserpine and from the serum of tumor-bearing mice receiving reserpine were examined to determine changes in EV release and EV content.

Results: TNBC cells progress to metastasis in mice lacking the IFN1-induced gene cholesterol-25 hydroxylase (CH25H) or expressing the IFNAR1^S526 knock-in that cannot be downregulated. Reserpine suppresses EV release from TNBC cells in vitro and in vivo. Western blot analysis demonstrated reserpine decreased NUPR1 protein levels in EVs. RNAseq analysis demonstrated that endothelial cells lacking CH25H treated with TEVs exhibited increased NUPR1 expression that was decreased by adding reserpine with the TEVs. NUPR1 overexpression upregulated genes that mediate TEV biogenesis and incorporation. Knockdown of NUPR1 with shRNA decreased the release of TEVs.

Conclusion: In conclusion, our study suggests that TNBC is driven by aberrant packaging of NUPR1 into TEVs which were transferred into recipient cells to activate pro-metastatic transcription driven by NUPR1.

Keywords

Extracellular vesicles / NUPR1 / triple-negative breast cancer / chemotherapy / type 1 interferon signaling

References

[1] Dent R,Pritchard KI.Triple-negative breast cancer: clinical features and patterns of recurrence.Clin Cancer Res2007;13:4429-34

[2] Gluz O,Gottschalk N,Nitz U.Triple-negative breast cancer--current status and future directions.Ann Oncol2009;20:1913-27

[3] Roshanzamir F,Cook D,Nielsen J.Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures.Proc Natl Acad Sci U S A2022;119:e2205456119 PMCID:PMC9436376

[4] Zhao T,Zhang Y,Lu X.Paclitaxel resistance modulated by the interaction between TRPS1 and AF178030.2 in triple-negative breast cancer.Evid Based Complement Alternat Med2022;2022:6019975 PMCID:PMC8986375

[5] Keklikoglou I,Güç E.Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models.Nat Cell Biol2019;21:190-202 PMCID:PMC6525097

[6] Volk-Draper L,Griggs C.Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.Cancer Res2014;74:5421-34 PMCID:PMC4185415

[7] Bidwell BN,Withana NP.Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.Nat Med2012;18:1224-31

[8] Buzdar AU,Kau SW.Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.J Clin Oncol1992;10:1540-6

[9] Cheon H,Schoggins JW.IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage.EMBO J2013;32:2751-63 PMCID:PMC3801437

[10] Doherty MR,Junk DJ.Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.Proc Natl Acad Sci U S A2017;114:13792-7 PMCID:PMC5748193

[11] Hussain T,Bordbari S.IFNAR1 deficiency impairs immunostimulatory properties of neutrophils in tumor-draining lymph nodes.Front Immunol2022;13:878959 PMCID:PMC9271705

[12] Liu SY,Chikere K.Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol.Immunity2013;38:92-105 PMCID:PMC3698975

[13] Ortiz A,Zahedi F.An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles.Cancer Cell2019;35:33-45.e6 PMCID:PMC6336114

[14] Rautela J,Slaney CY.Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer.Cancer Immunol Res2015;3:1207-17

[15] Lan Q,Duffey N.Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer.Oncogene2019;38:2814-29 PMCID:PMC6477891

[16] Odnokoz O,Peck AR.Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers.Cancer Biol Ther2020;21:629-36 PMCID:PMC7515508

[17] Chen D,Fang L.Hexavalent chromium (Cr(VI)) down-regulates acetylation of histone H4 at lysine 16 through induction of stressor protein Nupr1.PLoS One2016;11:e0157317 PMCID:PMC4902237

[18] Chowdhury UR,Fodstad O.Emerging role of nuclear protein 1 (NUPR1) in cancer biology.Cancer Metastasis Rev2009;28:225-32

[19] Emma MR,Bachvarov D.NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.Cell Death Dis2016;7:e2269 PMCID:PMC5143401

[20] Wang L,Yin Y.Transcriptional coregualtor NUPR1 maintains tamoxifen resistance in breast cancer cells.Cell Death Dis2021;12:149 PMCID:PMC7862277

[21] Xiao H,Chen X.NUPR1 promotes the proliferation and migration of breast cancer cells by activating TFE3 transcription to induce autophagy.Exp Cell Res2022;418:113234

[22] Murphy A,Sun H,Costa M.Induction of NUPR1 and AP-1 contributes to the carcinogenic potential of nickel.Oncol Rep2021;45:41 PMCID:PMC8365176

[23] Peinado H,Lavotshkin S.Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET.Nat Med2012;18:883-91

[24] Goldman MJ,Hastie M.Visualizing and interpreting cancer genomics data via the Xena platform.Nat Biotechnol2020;38:675-8 PMCID:PMC7386072

[25] Davies ML,Sanders AJ,Jiang WG.The transcript expression and protein distribution pattern in human colorectal carcinoma reveal a pivotal role of COM-1/p8 as a tumour suppressor.Cancer Genomics Proteomics2010;7:75-80.

[26] Legrier ME,Gaston J.Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer.Br J Cancer2016;114:177-87 PMCID:PMC4815803

[27] Lamsal A,Johansson I.Opposite and dynamic regulation of the interferon response in metastatic and non-metastatic breast cancer.Cell Commun Signal2023;21:50 PMCID:PMC9990226

[28] Weichselbaum RR,Yoon T.An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer.Proc Natl Acad Sci U S A2008;105:18490-5 PMCID:PMC2587578

[29] Katlinskaya YV,Yu Q.Suppression of type I interferon signaling overcomes oncogene-induced senescence and mediates melanoma development and progression.Cell Rep2016;15:171-80 PMCID:PMC4826807

[30] Katlinski KV,Katlinskaya YV.Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment.Cancer Cell2017;31:194-207 PMCID:PMC5313042

[31] Kloudova-Spalenkova A,Wei S,Peter Guengerich F.Plasma oxysterol levels in luminal subtype breast cancer patients are associated with clinical data.J Steroid Biochem Mol Biol2020;197:105566 PMCID:PMC7015808

[32] Li Y,Chen Y,Ze Y.Irradiated cell-derived exosomes transmit essential molecules inducing radiation therapy resistance.Int J Radiat Oncol Biol Phys2022;113:192-202

[33] Ning T,He Y.Exosomal miR-208b related with oxaliplatin resistance promotes Treg expansion in colorectal cancer.Mol Ther2021;29:2723-36 PMCID:PMC8417448

[34] Turiello R,Morretta E.Exosomal CD73 from serum of patients with melanoma suppresses lymphocyte functions and is associated with therapy resistance to anti-PD-1 agents.J Immunother Cancer2022;10:e004043 PMCID:PMC8915288

[35] Lu Z,Verginadis II.Regulation of intercellular biomolecule transfer-driven tumor angiogenesis and responses to anticancer therapies.J Clin Invest2021;131:e144225 PMCID:PMC8121529